358 related articles for article (PubMed ID: 28008176)
1. Trends in overall survival and costs of multiple myeloma, 2000-2014.
Fonseca R; Abouzaid S; Bonafede M; Cai Q; Parikh K; Cosler L; Richardson P
Leukemia; 2017 Sep; 31(9):1915-1921. PubMed ID: 28008176
[TBL] [Abstract][Full Text] [Related]
2. Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States.
Maiese EM; Evans KA; Chu BC; Irwin DE
Am Health Drug Benefits; 2018 Feb; 11(1):39-46. PubMed ID: 29692879
[TBL] [Abstract][Full Text] [Related]
3. Costs Associated with Productivity Loss Among U.S. Patients Newly Diagnosed with Multiple Myeloma Receiving Oral Versus Injectable Chemotherapy.
Merola D; Yong C; Noga SJ; Shermock KM
J Manag Care Spec Pharm; 2018 Oct; 24(10):1019-1026. PubMed ID: 30247101
[TBL] [Abstract][Full Text] [Related]
4. The impact of changed treatment patterns in multiple myeloma on health-care utilisation and costs, myeloma complications, and survival: A population-based comparison between two time periods in Denmark.
Hannig LH; Nielsen LK; Ibsen R; Arnheim-Dahlström L; Kjellberg J; Abildgaard N
Eur J Haematol; 2021 Jul; 107(1):63-73. PubMed ID: 33675553
[TBL] [Abstract][Full Text] [Related]
5. Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: A retrospective US claims database analysis.
Yang J; Boytsov N; Carlson JJ; Barthold D
J Manag Care Spec Pharm; 2023 Aug; 29(8):917-926. PubMed ID: 37523320
[No Abstract] [Full Text] [Related]
6. Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system.
Brøndum RF; Vestergaard AS; Børty L; Vesteghem C; Rytter AS; Nielsen MM; Severinsen MT; Jensen P; Gregersen H; El-Galaly TC; Dybkær K; Ehlers LH; Bøgsted M; Roug AS
Future Oncol; 2021 Sep; 17(25):3331-3341. PubMed ID: 34156281
[TBL] [Abstract][Full Text] [Related]
7. Impact of the affordability of novel agents in patients with multiple myeloma: Real-world data of current clinical practice in Mexico.
Tarín-Arzaga L; Arredondo-Campos D; Martínez-Pacheco V; Martínez-González O; Ramírez-López A; Gómez-De León A; Gutiérrez-Aguirre CH; Cantú-Rodríguez O; Jaime-Pérez JC; Gómez-Almaguer D
Cancer; 2018 May; 124(9):1946-1953. PubMed ID: 29461639
[TBL] [Abstract][Full Text] [Related]
8. A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.
Blommestein HM; Verelst SG; de Groot S; Huijgens PC; Sonneveld P; Uyl-de Groot CA
Eur J Haematol; 2016 Feb; 96(2):198-208. PubMed ID: 25892333
[TBL] [Abstract][Full Text] [Related]
9. Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities.
Ailawadhi S; Frank RD; Sharma M; Menghani R; Temkit M; Paulus S; Khera N; Hashmi S; Advani P; Swaika A; Paulus A; Aslam N; Sher T; Roy V; Colon-Otero G; Chanan-Khan A
Cancer; 2018 Apr; 124(8):1710-1721. PubMed ID: 29360160
[TBL] [Abstract][Full Text] [Related]
10. Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.
Gaultney JG; Franken MG; Tan SS; Redekop WK; Huijgens PC; Sonneveld P; Uyl-de Groot CA
J Clin Pharm Ther; 2013 Feb; 38(1):41-7. PubMed ID: 23126374
[TBL] [Abstract][Full Text] [Related]
11. Healthcare resource use and costs associated with chronic kidney disease in US private insurance patients with multiple myeloma.
Bhowmik D; Song X; Intorcia M; Kent ST; Shi N
J Oncol Pharm Pract; 2019 Jun; 25(4):855-864. PubMed ID: 29661050
[TBL] [Abstract][Full Text] [Related]
12. Real-world outcome and healthcare costs of relapsed or refractory multiple myeloma: A retrospective analysis from the Chinese experience.
Zhou X; Xia J; Mao J; Cheng F; Qian X; Guo H
Hematology; 2016 Jun; 21(5):280-6. PubMed ID: 26900623
[TBL] [Abstract][Full Text] [Related]
13. Frequency of skeletal-related events and associated healthcare resource use and costs in US patients with multiple myeloma.
Nash Smyth E; Conti I; Wooldridge JE; Bowman L; Li L; Nelson DR; Ball DE
J Med Econ; 2016; 19(5):477-86. PubMed ID: 26671598
[TBL] [Abstract][Full Text] [Related]
14. Estimating the Economic Impact of Adding Panobinostat to a U.S. Formulary for Relapsed and/or Refractory Multiple Myeloma: A Budget Impact and Cost-Benefit Model.
Bloudek L; Roy A; Kish JK; Siegel DS; Jagannath S; Globe D; Orloski L; Kuriakose ET
J Manag Care Spec Pharm; 2016 Aug; 22(8):991-1002. PubMed ID: 27459662
[TBL] [Abstract][Full Text] [Related]
15. Economic and clinical impact of multiple myeloma to managed care.
Cook R
J Manag Care Pharm; 2008 Sep; 14(7 Suppl):19-25. PubMed ID: 18774882
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results-Medicare Database.
Shah GL; Winn AN; Lin PJ; Klein A; Sprague KA; Smith HP; Buchsbaum R; Cohen JT; Miller KB; Comenzo R; Parsons SK
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1823-9. PubMed ID: 26033281
[TBL] [Abstract][Full Text] [Related]
17. A descriptive cost-analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high-dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
Monteith BE; Venner CP; Cheung MC; Pater J; Shepherd L; Richardson H; Reece D; Gul E; Lalancette M; Castonguay V; Kukreti V; Tiedemann R; Phua C; Bhella S; Dudebout J; Sherry M; Yen H; Chen BE; Hay AE
Eur J Haematol; 2021 Sep; 107(3):333-342. PubMed ID: 34053112
[TBL] [Abstract][Full Text] [Related]
18. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
Chari A; Parikh K; Ni Q; Abouzaid S
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
[TBL] [Abstract][Full Text] [Related]
19. Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myeloma.
Arikian SR; Milentijevic D; Binder G; Gibson CJ; Hu XH; Nagarwala Y; Hussein M; Corvino FA; Surinach A; Usmani SZ
Curr Med Res Opin; 2015 Jun; 31(6):1105-15. PubMed ID: 25785551
[TBL] [Abstract][Full Text] [Related]
20. Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal.
Antunes L; Rocha-Gonçalves F; Chacim S; Lefèvre C; Pereira M; Pereira S; Zagorska A; Bento MJ
Eur J Cancer Care (Engl); 2019 Jul; 28(4):e13026. PubMed ID: 30828907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
